Intellia (NTLA) Director Brian Goff Receives Equity Awards

What Happened

• Brian Goff, a director of Intellia Therapeutics (NTLA), was granted equity awards on June 9, 2026: 9,200 restricted stock units (RSUs) and a 13,300-share derivative award. Both grants show an acquisition price of $0.00 (typical for compensation awards) and were reported on a Form 4 filed June 10, 2026.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-10 (timely filing).
• Awards: 9,200 RSUs (grant price $0.00) and 13,300-share derivative award (grant price $0.00).
• Shares owned after transaction: not specified in the provided summary (filing did not disclose total beneficial ownership here).
• Footnotes: F1 — the 9,200 awards are RSUs, each representing a contingent right to one share. F2 — the 13,300-share derivative award vests in full on the earlier of (a) the first anniversary of the grant or (b) the next annual meeting of stockholders.
• No cash changed hands; these are compensation grants (transaction code A).

Context

• These are grants of equity compensation, not open‑market purchases or sales, and are typically part of director pay rather than an immediate market bet. The derivative award has a short vesting trigger (up to one year or next annual meeting), so shares are not necessarily issued immediately.